Table of Contents

1 Product Introduction and Overview

• 1.1 Product Definition
• 1.2 Product Specification
• 1.3 Global Market Overview
  • 1.3.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Status and Forecast (2017-2028)
  • 1.3.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value CAGR by Region
• 1.4 Market Drivers, Inhibitors
  • 1.4.1 Market Drivers
  • 1.4.2 Market Inhibitors
  • 1.4.3 COVID-19 Impact Analysis

2 Global Age-Related Macular Degeneration (AMD) Therapeutics Supply by Company

• 2.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Volume by Company
• 2.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value by Company
• 2.3 Global Age-Related Macular Degeneration (AMD) Therapeutics Price by Company
• 2.4 Age-Related Macular Degeneration (AMD) Therapeutics Production Location and Sales Area of Main Manufacturers
• 2.5 Trend of Concentration Rate

3 Global and Regional Age-Related Macular Degeneration (AMD) Therapeutics Market Status by Type

• 3.1 Age-Related Macular Degeneration (AMD) Therapeutics Type Introduction
  • 3.1.1 Wet AMD
  • 3.1.2 Dry AMD
• 3.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Market by Type
  • 3.2.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Volume by Type (2017-2022)
  • 3.2.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value by Type (2017-2022)
  • 3.2.3 Global Age-Related Macular Degeneration (AMD) Therapeutics Price by Type (2017-2022)
• 3.3 North America: by Type
• 3.4 Europe: by Type
• 3.5 Asia Pacific: by Type
• 3.6 Central & South America: by Type
• 3.7 Middle East & Africa: by Type

4 Global and Regional Age-Related Macular Degeneration (AMD) Therapeutics Market Status by Application

• 4.1 Age-Related Macular Degeneration (AMD) Therapeutics Segment by Application
  • 4.1.1 Hospital
  • 4.1.2 Clinic
  • 4.1.3 Research Institute
  • 4.1.4 Other
• 4.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Market by Application
  • 4.2.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Volume by Application (2017-2022)
  • 4.2.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value by Application (2017-2022)
  • 4.2.3 Global Age-Related Macular Degeneration (AMD) Therapeutics Price by Application (2017-2022)
• 4.3 North America: by Application
• 4.4 Europe: by Application
• 4.5 Asia Pacific: by Application
• 4.6 Central & South America: by Application
• 4.7 Middle East & Africa: by Application

5 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Status by Region

• 5.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market by Region
  • 5.1.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Volume by Region
  • 5.1.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value by Region
• 5.2 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Status
• 5.3 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Status
• 5.4 Asia Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Status
• 5.5 Central & South America Age-Related Macular Degeneration (AMD) Therapeutics Market Status
• 5.6 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Status

6 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Status

• 6.1 North America Age-Related Macular Degeneration (AMD) Therapeutics Market by Country
  • 6.1.1 North America Age-Related Macular Degeneration (AMD) Therapeutics Sales Volume by Country (2017-2022)
  • 6.1.2 North America Age-Related Macular Degeneration (AMD) Therapeutics Sales Value by Country (2017-2022)
• 6.2 United States
• 6.3 Canada
• 6.4 Mexico

7 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Status

• 7.1 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market by Country
  • 7.1.1 Europe Age-Related Macular Degeneration (AMD) Therapeutics Sales Volume by Country (2017-2022)
  • 7.1.2 Europe Age-Related Macular Degeneration (AMD) Therapeutics Sales Value by Country (2017-2022)
• 7.2 Germany
• 7.3 France
• 7.4 UK
• 7.5 Italy
• 7.6 Russia
• 7.7 Spain

8 Asia Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Status

• 8.1 Asia Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market by Country
  • 8.1.1 Asia Pacific Age-Related Macular Degeneration (AMD) Therapeutics Sales Volume by Country (2017-2022)
  • 8.1.2 Asia Pacific Age-Related Macular Degeneration (AMD) Therapeutics Sales Value by Country (2017-2022)
• 8.2 China
• 8.3 Japan
• 8.4 Korea
• 8.5 Southeast Asia
• 8.6 India
• 8.7 Australasia

9 Central & South America Age-Related Macular Degeneration (AMD) Therapeutics Market Status

• 9.1 Central & South America Age-Related Macular Degeneration (AMD) Therapeutics Market by Country
  • 9.1.1 Central & South America Age-Related Macular Degeneration (AMD) Therapeutics Sales Volume by Country (2017-2022)
  • 9.1.2 Central & South America Age-Related Macular Degeneration (AMD) Therapeutics Sales Value by Country (2017-2022)
• 9.2 Brazil
• 9.3 Argentina
• 9.4 Colombia

10 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Status

• 10.1 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market by Country
  • 10.1.1 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Sales Volume by Country (2017-2022)
  • 10.1.2 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Sales Value by Country (2017-2022)
• 10.2 Iran
• 10.3 Israel
• 10.4 Turkey
• 10.5 South Africa
• 10.8 Saudi Arabia

11 Supply Chain and Manufacturing Cost Analysis

• 11.1 Supply Chain Analysis
• 11.2 Production Process Chart Analysis
• 11.3 Raw Materials and Key Suppliers Analysis
  • 11.3.1 Raw Materials Introduction
  • 11.3.2 Raw Materials Key Suppliers List
• 11.4 Age-Related Macular Degeneration (AMD) Therapeutics Manufacturing Cost Analysis
• 11.5 Age-Related Macular Degeneration (AMD) Therapeutics Sales Channel and Distributors Analysis
  • 11.5.1 Age-Related Macular Degeneration (AMD) Therapeutics Sales Channel
  • 11.5.2 Age-Related Macular Degeneration (AMD) Therapeutics Distributors
• 11.6 Age-Related Macular Degeneration (AMD) Therapeutics Downstream Major Buyers

12 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast by Type and by Application

• 12.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Volume and Sales Value Forecast (2023-2028)
• 12.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Forecast by Type
  • 12.2.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Volume Forecast by Type
  • 12.2.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Forecast by Type
  • 12.2.3 Global Age-Related Macular Degeneration (AMD) Therapeutics Price Forecast by Type
• 12.3 Global Age-Related Macular Degeneration (AMD) Therapeutics Forecast by Application
  • 12.3.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Volume Forecast by Application
  • 12.3.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Forecast by Application
  • 12.3.3 Global Age-Related Macular Degeneration (AMD) Therapeutics Price Forecast by Application

13 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast by Region/Country

• 13.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast by Region (2023-2028)
  • 13.1.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Volume Forecast by Region (2023-2028)
  • 13.1.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Sales Value Forecast by Region (2023-2028)
• 13.2 North America Market Forecast
• 13.3 Europe Market Forecast
• 13.4 Asia Pacific Market Forecast
• 13.5 Central & South America Market Forecast
• 13.6 Middle East & Africa Market Forecast

14 Key Participants Company Information

• 14.1 Regeneron Pharmaceuticals Inc.
  • 14.1.1 Company Information
  • 14.1.2 Age-Related Macular Degeneration (AMD) Therapeutics Product Introduction
  • 14.1.3 Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Sales Volume, Price, Sales Value and Gross Margin (2020-2022)
  • 14.1.4 SWOT Analysis
• 14.2 Novartis AG
  • 14.2.1 Company Information
  • 14.2.2 Age-Related Macular Degeneration (AMD) Therapeutics Product Introduction
  • 14.2.3 Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Sales Volume, Price, Sales Value and Gross Margin (2020-2022)
  • 14.2.4 SWOT Analysis
• 14.3 F. Hoffmann-La Roche Ltd.
  • 14.3.1 Company Information
  • 14.3.2 Age-Related Macular Degeneration (AMD) Therapeutics Product Introduction
  • 14.3.3 F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Sales Volume, Price, Sales Value and Gross Margin (2020-2022)
  • 14.3.4 SWOT Analysis
• 14.4 Bausch Health Companies, Inc.
  • 14.4.1 Company Information
  • 14.4.2 Age-Related Macular Degeneration (AMD) Therapeutics Product Introduction
  • 14.4.3 Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Sales Volume, Price, Sales Value and Gross Margin (2020-2022)
  • 14.4.4 SWOT Analysis
• 14.5 Amgen Inc.
  • 14.5.1 Company Information
  • 14.5.2 Age-Related Macular Degeneration (AMD) Therapeutics Product Introduction
  • 14.5.3 Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Sales Volume, Price, Sales Value and Gross Margin (2020-2022)
  • 14.5.4 SWOT Analysis

...

15 Conclusion

16 Methodology

This report provides a comprehensive analysis of current global Age-Related Macular Degeneration (AMD) Therapeutics market based on segmented types and downstream applications. Major product development trends are discussed under major downstream segment scenario. This report also focuses on major driving factors and inhibitors that affect the market and competitive landscape. Global and regional leading players in the Age-Related Macular Degeneration (AMD) Therapeutics industry are profiled in a detailed way, with sales data and market share info. This report also includes global and regional market size and forecast, drill-down to top 20 economies.

According to this survey, the global Age-Related Macular Degeneration (AMD) Therapeutics market is estimated at $ million in 2021, and projected to grow at a CAGR of % to $ million by 2028.

Covid-19 pandemic has impacted the supply and demand status for many industries along the supply chain. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Opportunties and Forecast 2022-2028 report makes a brilliant attempt to unveil key opportunities available in the global Age-Related Macular Degeneration (AMD) Therapeutics market under the covid-19 impact to help readers in achieving a better market position. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information.

The Global Age-Related Macular Degeneration (AMD) Therapeutics Market has been exhibited in detail in the following chapters
Chapter 1 displays the basic product introduction and market overview.
Chapter 2 provides the competition landscape of global Age-Related Macular Degeneration (AMD) Therapeutics industry.
Chapter 3 provides the market analysis by type and by region
Chapter 4 provides the market analysis by application and by region
Chapter 5-10 presents regional and country market size and forecast, under the context of market drivers and inhibitors analysis.
Chapter 11 analyses the supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis.
Chapter 12 provides the market forecast by type and by application
Chapter 13 provides the market forecast by region
Chapter 14 profiles global leading players with their revenue, market share, profit margin, major product portfolio and SWOT analysis.
Chapter 15 conclusions

Segmented by Type
Wet AMD
Dry AMD

Segmented by Application
Hospital
Clinic
Research Institute
Other

Segmented by Country
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Spain
Asia Pacific
China
Japan
Korea
Southeast Asia
India
Australasia
Central & South America
Brazil
Argentina
Colombia
Middle East & Africa
Iran
Israel
Turkey
South Africa
Saudi Arabia

Key manufacturers included in this survey
F. Hoffmann-La Roche Ltd.
Bausch Health Companies, Inc.
Amgen Inc.